Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient.
Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient.
复制标题
黑色素瘤患者中维莫非尼诱导的角化棘皮瘤样丘疹中 ATP2A2 基因的表达降低。
DOI：
10.1111/ijd.13430
复制
发表时间：
2017
期刊：
影响因子：
3.6
通讯作者：
Tsuboi R
中科院分区：
文献类型：
--
作者：
Wakimoto H;Harada K;Arai T;Maeda T;Irisawa R;Tsuboi R
该文章描述了1例58岁女性患者，有IV期转移性黑色素瘤病史，接受维罗非尼治疗，在角化棘皮瘤样丘疹伴棘层松解中出现ATP 2A2基因表达降低。经体格检查、组织病理学检查和病理学分析后确诊。讨论了维罗非尼在鳞状细胞癌（SCC）和疣状角化病发生中的作用。
The article describes the case of a 58-year-old female patient with a history of stage IV metastatic melanoma treated with vemurafenib, and who developed a decrease in ATP2A2 gene expression in keratoacanthoma-like papules with acantholysis. The diagnosis was confirmed after performing physical assessment, histopathologic examination and pathological analysis. The role of vemurafenib in the occurrence of squamous cell carcinoma (SCC) and verrucal keraosis is discussed.